← Back to Screener
Eton Pharmaceutcials, Inc. Common Stock (ETON)
Price$24.43
Favorite Metrics
Price vs S&P 500 (26W)24.87%
Price vs S&P 500 (4W)35.98%
Market Capitalization$735.86M
All Metrics
P/CF (Annual)69.92x
Book Value / Share (Quarterly)$0.97
P/TBV (Annual)10.47x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)55.53%
Cash Flow / Share (Quarterly)$0.38
Price vs S&P 500 (YTD)56.85%
Gross Margin (TTM)53.46%
Net Profit Margin (TTM)-5.75%
EPS (TTM)$-0.17
10-Day Avg Trading Volume0.43M
EPS Excl Extra (TTM)$-0.17
Revenue Growth (5Y)357.25%
EPS (Annual)$-0.17
ROI (Annual)-8.11%
Gross Margin (Annual)53.46%
Net Profit Margin (5Y Avg)-13.99%
Cash / Share (Quarterly)$0.96
Revenue Growth QoQ (YoY)82.72%
ROA (Last FY)-4.99%
Revenue Growth TTM (YoY)104.94%
EBITD / Share (TTM)$0.12
ROE (5Y Avg)-23.87%
Operating Margin (TTM)-1.06%
Cash Flow / Share (Annual)$0.38
P/B Ratio28.14x
P/B Ratio (Quarterly)17.34x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)9.26x
Net Interest Coverage (TTM)-0.23x
ROA (TTM)-4.81%
EV / EBITDA (TTM)231.40x
EPS Incl Extra (Annual)$-0.17
Current Ratio (Annual)1.57x
Quick Ratio (Quarterly)0.98x
3-Month Avg Trading Volume0.31M
52-Week Price Return96.57%
EV / Free Cash Flow (Annual)72.66x
Revenue / Employee (TTM)$3
Tangible BV / Share (Quarterly)$0.39
P/S Ratio (Annual)9.20x
Asset Turnover (Annual)0.87x
52-Week High$27.29
Operating Margin (5Y Avg)-11.57%
EPS Excl Extra (Annual)$-0.17
CapEx CAGR (5Y)46.12%
Tangible BV CAGR (5Y)-7.25%
26-Week Price Return28.86%
Quick Ratio (Annual)0.98x
13-Week Price Return74.34%
Total Debt / Equity (Annual)1.17x
Current Ratio (Quarterly)1.57x
Enterprise Value$740.479
Revenue / Share Growth (5Y)335.35%
Asset Turnover (TTM)0.84x
Book Value / Share Growth (5Y)8.46%
Revenue / Employee (Annual)$3
Inventory Turnover (Annual)2.43x
Pretax Margin (Annual)-5.70%
Cash / Share (Annual)$0.96
3-Month Return Std Dev50.66%
Gross Margin (5Y Avg)66.90%
Net Income / Employee (TTM)$-0
ROE (Last FY)-17.59%
Net Interest Coverage (Annual)-0.23x
EPS Basic Excl Extra (Annual)$-0.17
P/FCF (TTM)33.77x
Receivables Turnover (TTM)9.34x
EV / Free Cash Flow (TTM)72.66x
Total Debt / Equity (Quarterly)1.17x
EPS Incl Extra (TTM)$-0.17
Receivables Turnover (Annual)9.34x
ROI (TTM)-8.41%
P/S Ratio (TTM)9.20x
Pretax Margin (5Y Avg)-13.81%
Revenue / Share (Annual)$2.97
Tangible BV / Share (Annual)$0.42
Forward P/E29.43x
Price vs S&P 500 (52W)66.74%
Year-to-Date Return59.49%
5-Day Price Return-0.48%
EPS Normalized (Annual)$-0.17
ROA (5Y Avg)-11.23%
Net Profit Margin (Annual)-5.75%
Month-to-Date Return9.28%
Cash Flow / Share (TTM)$0.12
EBITD / Share (Annual)$0.12
Operating Margin (Annual)-1.06%
LT Debt / Equity (Annual)0.83x
P/CF (TTM)69.92x
ROI (5Y Avg)-14.79%
LT Debt / Equity (Quarterly)0.83x
EPS Basic Excl Extra (TTM)$-0.17
P/TBV (Quarterly)15.31x
P/B Ratio (Annual)17.34x
Inventory Turnover (TTM)2.43x
Pretax Margin (TTM)-5.70%
Book Value / Share (Annual)$0.97
Price vs S&P 500 (13W)73.65%
Beta0.94x
P/FCF (Annual)72.21x
Revenue / Share (TTM)$2.97
ROE (TTM)-18.84%
52-Week Low$12.25
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ETONEton Pharmaceutcials, Inc. Common Stock | 9.20x | 104.94% | 53.46% | — | $24.43 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Eton Pharmaceuticals is a specialty pharmaceutical company focused on rare diseases with significant unmet patient needs. The company markets four FDA-approved products addressing adrenocortical insufficiency, hyperammonemia, homocystinuria, and hereditary tyrosinemia type 1. Eton is advancing three late-stage product candidates, including an innovative hydrocortisone autoinjector, to expand its rare disease portfolio.